Health Bulletin 9/December/2021

Published On 2021-12-09 12:07 GMT   |   Update On 2021-12-09 12:07 GMT
Advertisement

Here are Top Health stories of the day

NEET PG Counselling Delay: Health Ministry Urges SC for Speedy Hearing, Doctors warn of protest escalation

Although there is no solution to the pending NEET PG Counselling process and the continuous protest by the resident doctors across the country, the Union Health Ministry has recently urged the Supreme Court for early listing and hearing of the matter on the EWS reservation matter.

Advertisement

This comes after the Health Minister himself had promised the resident doctors at RML Hospital that the Central Government would press for an early hearing of the matter.

For more details, check out the full story on the link below:

NEET PG Counselling Delay: Health Ministry Urges SC For Speedy Hearing, Doctors Warn Of Protest Escalation


IMA warns of 'massive third wave' amid Omicron threat, urges public to follow COVID-19 protocols

The Indian Medical Association (IMA) urged the government to announce "additional" doses of Covid vaccine for healthcare, frontline workers, and immunocompromised individuals amid concerns over Omicron, 21 cases of which have been detected in India so far.

It also demanded that the government expedite the proposal of vaccinating individuals aged 12 to 18 years.

For more details, check out the full story on the link below:

3rd Wave Will Be There, Will Be Massive: IMA

13 lakh Plus Registered Allopathic doctors, 596 Medical Colleges in India: Health Minister

As of November 2021, the number of registered medical practitioners in India is more than 13 lakhs, informed Dr. Bharati Pravin Pawar, the MoS Health.

The Minister of Health has further informed the upper house of the Parliament that the doctor-patient ratio in India is 1:834, better than WHO recommendation, assuming 80% availability of registered allopathic doctors and 5.65 lakh AYUSH practitioners.

For more details, check out the full story on the link below:

13 Lakh Plus Registered Allopathic Doctors, 596 Medical Colleges In India: Health Minister

AIIMS INI CET January 2022 session: 41 MD, MS seats up available for PwBD candidates

Through a recent notice, the All India Institute of Medical Sciences (AIIMS), has released the Final Seat Position for candidates seeking PG medical admissions via INI-CET January 2022 session in Persons with Benchmark Disabilities (PwBD) category this academic year.

According to the seat position, a total of 41 MD, MS seats are available for disabled candidates this year across AIIMS.

For more details, check out the full story on the link below:

AIIMS INI CET January 2022 Session: 41 MD, MS Seats Up Available For PwBD Candidates

Alembic Pharma gets USFDA nod for pulmonary arterial hypertension drug Selexipag

Drugmaker, Alembic Pharmaceuticals Limited, announced that the company has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Selexipag Tablets, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 mcg, and 1,600 mcg.

The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Uptravi Tablets, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 mcg, and 1,600 mcg, of Actelion Pharmaceuticals, Ltd. (Actelion).

For more details, check out the full story on the link below:

Alembic Pharma Gets USFDA Nod For Pulmonary Arterial Hypertension Drug Selexipag

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News